They have a holistic understanding of different markets. This enables the team to make crucial changes to a specific project based on the market of their clients’ preferences—be itthe U.S., Europe, or APAC. The ability to operate on a global scale has turned EVERSANA into a leader in this space.

The capable team has equipped EVERSANA with the capability to serve numerous global pharmaceutical companies. Many of the company’s clients, in fact, have been working with it for years now.
For instance, one of EVERSANA’s HEOR clients developed a new drug for non-small cell lung cancer. The client was striving to evaluate multiple lines of therapy to understand how the drug could benefit payers in different ways. EVERSANA’s HEOR and Value & Evidence team developed a sophisticated micro simulation called discrete event simulation to simulate the patient profiles across Canada as they move from their diagnosis to multiple lines of therapy while predicting cost and outcomes. The model is currently being used by clients beyond Canada for different therapeutic indications.

EVERSANA’s indomitable fervor to drive clients through all the complexities allows it to continuously improve healthcare outcomes. The company understands that commercializing a new product in the market is no less than an uphill journey, requiring pharmaceutical companies to address the demand of different stakeholders, including regulators, patients, and payers. Given this situation, a partner like EVERSANA and specifically their best-in-class value & evidence solutions can really make a difference by supporting clients from pre-launch to post-launch.